Skip to main content
. 2016 Feb 8;7:10656. doi: 10.1038/ncomms10656

Figure 8. The Arf6-based mesenchymal pathway in poor clinical outcome of ccRCC patients.

Figure 8

(a) Representative images of immunohistochemical staining of LPAR2, EFA6B, AMAP1 and EPB41L5 in human primary ccRCC specimens. Scale bars, 50 μm. (b–d) Kaplan–Meier curves of the overall survival and progression-free survival of ccRCC patients (n=120), with regard to the expression levels of each single component of the Arf6 pathway (b), with regard to the high expression of all components (c), and with regard to the simultaneous high expression of AMAP1 and EPB41L5 (d), as indicated. P values represent the results of the log-rank test.